[{"id":"aec8c31d-7488-4935-b5b7-dd30f1b33a68","acronym":"","url":"https://clinicaltrials.gov/study/NCT01966445","created_at":"2021-01-18T08:56:18.757Z","updated_at":"2024-07-02T16:36:58.502Z","phase":"Phase 1","brief_title":"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors","source_id_and_acronym":"NCT01966445","lead_sponsor":"GlaxoSmithKline","biomarkers":" ERBB3 • CA 19-9","pipe":"","alterations":" ","tags":["ERBB3 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2849330"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/26/2013","start_date":" 11/26/2013","primary_txt":" Primary completion: 09/18/2017","primary_completion_date":" 09/18/2017","study_txt":" Completion: 09/18/2017","study_completion_date":" 09/18/2017","last_update_posted":"2019-07-01"},{"id":"e87aedf6-d57c-48bd-b9d5-e959819f1c59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02345174","created_at":"2021-01-18T11:09:08.618Z","updated_at":"2024-07-02T16:37:02.615Z","phase":"Phase 1","brief_title":"Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors","source_id_and_acronym":"NCT02345174","lead_sponsor":"GlaxoSmithKline","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2849330"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/19/2015","start_date":" 03/19/2015","primary_txt":" Primary completion: 06/02/2016","primary_completion_date":" 06/02/2016","study_txt":" Completion: 06/02/2016","study_completion_date":" 06/02/2016","last_update_posted":"2019-02-21"}]